Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.

Proceedings of the National Academy of Sciences of the United States of America - 16 Aug 2016

Shi Xiarong, Sousa Leiliane P, Mandel-Bausch Elizabeth M, Tome Francisco, Reshetnyak Andrey V, Hadari Yaron, Schlessinger Joseph, Lax Irit

Abstract excerpt

Large genomic sequencing analysis as part of precision medicine efforts revealed numerous activating mutations in receptor tyrosine kinases, including KIT. Unfortunately, a single approach is not effective for inhibiting cancer cells or treating cancers driven by all known oncogenic KIT mutants. Here, we show that each of the six major KIT oncogenic mutants exhibits different enzymatic, cellular, and dynamic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to NIH 3T3 Cells

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 27482095
DOI: 10.1073/pnas.1610179113
PMCID: PMC4995958

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.PMID 27482095Read ↗

KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions.Semantic proximity Read ↗

A precision therapy against cancers driven by KIT/PDGFRA mutations.Semantic proximity Read ↗

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.Semantic proximity Read ↗

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.Semantic proximity Read ↗

The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.Semantic proximity Read ↗

Normal and oncogenic forms of the receptor tyrosine kinase kit.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

c-Kit Receptors as a Therapeutic Target in Cancer: Current InsightsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.